Novel transcript, antisense to FLOT2

The target “Novel transcript, antisense to FLOT2” (ENSG00000264304) is a long non-coding RNA classified as an antisense transcript relative to the FLOT2 gene[1][5]. Antisense transcripts are RNA molecules transcribed from the opposite strand relative to a reference gene; they are not protein-coding and instead have regulatory roles, often influencing the expression of the corresponding sense gene (here, FLOT2)[1][5][6][9]. Such antisense RNAs can modulate gene expression at the chromatin, transcriptional, or RNA stability levels, often altering chromatin marks and influencing the rates of sense transcript production, processing, and degradation[2][3][6][9]. While these effects can be important for basic gene regulation, there is no evidence this specific transcript functions as a druggable or recognized therapeutic target[1][5]. No direct evidence links ENSG00000264304 to a specific disease, nor does it have reported interactions with any drug or biomarker utility[1][5]. This “novel transcript, antisense to FLOT2” is likely a gene annotation or transcript model, not a validated protein, receptor, enzyme, or canonical therapeutic target, and therefore is not suitable for drug targeting or clinical applications[1][5]. There is nothing to suggest “novel transcript, antisense to FLOT2” is misspelled, but as an antisense lncRNA transcript, it does not meet common criteria for a therapeutic target (like receptor, transporter, enzyme, etc.) and is instead a non-coding regulatory transcript, making “is_incorrect: true” for this context[1][5]. Since it is not a named or standardized protein/gene target, canonical abbreviation, drug interactions, mechanism, biomarker use, or safety concerns are all null or not applicable[1][5][6].

Other names

ENSG00000264304novel antisense transcript to FLOT2